News | July 03, 2025
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Subscribe To Our Newsletter & Stay Updated
